Kalaris Therapeutics, Inc.
KLRS
$3.54
$0.164.73%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 618.27% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 303.98% | ||||
| Operating Income | -303.98% | ||||
| Income Before Tax | -199.27% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -199.27% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -199.27% | ||||
| EBIT | -303.98% | ||||
| EBITDA | -- | ||||
| EPS Basic | 3.09% | ||||
| Normalized Basic EPS | 3.09% | ||||
| EPS Diluted | 3.09% | ||||
| Normalized Diluted EPS | 3.09% | ||||
| Average Basic Shares Outstanding | 208.78% | ||||
| Average Diluted Shares Outstanding | 208.78% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||